| Product Name | Cyclic Somatostatin (Somatostatin-14) |
| Synonyms | SRIF-14; SST-14; growth hormone release-inhibiting factor (GHIH); somatotropin release-inhibiting factor; somatostatin acetate |
| CAS Number | 38916-34-6 (also reported as 51110-01-1) |
| Sequence (3-Letter) | H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH |
| Sequence (1-Letter) | AGCKNFFWKTFTSC (14 residues; free-acid C-terminus) |
| Disulfide Bridge | Cys3–Cys14 (intramolecular ring) |
| Molecular Formula | C₇₆H₁₀₄N₁₈O₁₉S₂ |
| Molecular Weight | 1637.9 |
| Category | Cyclopeptide – somatostatin-14 (native cyclic peptide hormone) |
| Purity | ≥98% (by HPLC); higher specifications available on request |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate or TFA (per specification) |
| Disulfide Bridge | Cys3–Cys14 (intramolecular) |
| Water Content | Per specification (Karl Fischer) |
| Solubility | Soluble in water and dilute aqueous acid |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg to gram (research and process development); larger scale on enquiry |
| QC Documentation | COA, HPLC, MS identity; amino-acid analysis and peptide content on request |
| Usage | For research and manufacturing use only. Not a finished medicine; not for human or veterinary use; not for sale to patients or individuals. Customers are responsible for regulatory and intellectual-property compliance in their territory. |
Cyclic Somatostatin, also called somatostatin-14 or SRIF-14, is a fourteen-residue cyclic peptide hormone with CAS 38916-34-6 and the molecular formula C76H104N18O19S2 in its free-acid form. Its one-letter sequence is AGCKNFFWKTFTSC, and it is closed into a ring by a disulfide bridge between the cysteine residues at positions three and fourteen. It is a natural growth hormone release-inhibiting factor, and we make it in-house and supply it as a synthetic lyophilized powder for research and manufacturing use.
The two cysteine side chains in somatostatin form a disulfide bond that links positions three and fourteen, turning the linear chain into a ring. This cyclic shape holds the key residues in the right positions to bind somatostatin receptors, so the disulfide bridge is essential for activity. The same kind of constrained ring is the reason somatostatin and its analogues are studied as cyclic peptides rather than simple linear sequences.
Native somatostatin has a very short lifetime in the body, so longer-acting cyclic analogues were developed from its active core. Octreotide, lanreotide, and pasireotide keep the receptor-binding part of somatostatin in a smaller, more stable ring, and they are used where long somatostatin-like activity is needed. Cyclic somatostatin itself is the parent scaffold these analogues are based on, which is why it is a common reference and starting point in somatostatin research.
We supply Cyclic Somatostatin as a synthetic peptide at high HPLC purity with a certificate of analysis, an HPLC chromatogram, and mass-spec identity confirmation. Research and process-development specifications are available, with amino-acid analysis and peptide content on request. Salt form, purity, and quantity can be set to your specification.
No. Cyclic Somatostatin supplied by SynPeptide is a raw material for research and pharmaceutical development, analysis, and manufacturing only. It is not a finished medicine, it is not for human or veterinary use, and it is not sold to patients or individuals for personal use. Any clinical or commercial medicinal use is the responsibility of an appropriately licensed party and is subject to the relevant regulatory approvals.
Cyclic Somatostatin (CAS 38916-34-6), better known as somatostatin-14 or SRIF-14, is the natural cyclic peptide hormone that inhibits the release of growth hormone and many other hormones. It is a fourteen-residue peptide closed into a ring by a single disulfide bridge, and we supply it as a synthetic peptide for research and manufacturing use. It is not supplied as a finished medicine and not for human use.
Cyclic Somatostatin has the sequence H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (one-letter AGCKNFFWKTFTSC) with a free-acid C-terminus. A disulfide bridge between Cys3 and Cys14 joins the two ends of the active part of the chain into a ring. Its molecular formula is C76H104N18O19S2 and its molecular weight is about 1637.9. It was first isolated from the hypothalamus and is also known as growth hormone release-inhibiting factor.
The single disulfide bond is what makes somatostatin a cyclic peptide. By tying positions three and fourteen together, it locks the central residues, including the Phe-Trp-Lys-Thr motif that contacts the receptor, into the shape needed for binding. Without the ring the peptide loses most of its activity, which is why correct disulfide formation is the central quality point when the peptide is made, and why cyclic peptides like this need controlled oxidation rather than simple chain assembly.
Somatostatin acts through a family of five G-protein-coupled receptors, named SST1 to SST5, found in the brain, pituitary, pancreas, and gut. Through these receptors it broadly inhibits secretion, reducing the release of growth hormone, glucagon, insulin, and several gastrointestinal hormones. This is provided as factual background; the material we supply is for research and analytical use, not for human or veterinary use, not for sale to patients, and carries no health or therapeutic claims.
Because native somatostatin is broken down quickly, more stable cyclic analogues were created from its receptor-binding core. Octreotide, lanreotide, and pasireotide are smaller cyclic peptides that keep somatostatin-like activity for much longer, and they are central targets in peptide manufacturing. Cyclic somatostatin is the parent scaffold behind this family, so it is widely used as a reference point and starting material in work on somatostatin analogues.
Cyclic Somatostatin is used as a research peptide in receptor and signalling studies, as a comparator in work on somatostatin analogues, and as a building block and reference in peptide process development. We supply it at research and process-development scale with full analytical data so it can be used reliably across these settings.
Store the lyophilized peptide at -20°C, kept dry and protected from light. Because the molecule depends on its Cys3–Cys14 disulfide bridge, avoid reducing conditions and strong oxidants that could open or scramble the ring, and protect the tryptophan residue from prolonged light to limit oxidation. The peptide dissolves in water and dilute aqueous acid; reconstitute in a suitable buffer, aliquot stock solutions to avoid repeated freeze-thaw, and follow the certificate of analysis for lot-specific peptide and water content.
We make Cyclic Somatostatin and related cyclic peptides by solid-phase synthesis with controlled disulfide formation, and release them with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with grade and salt form set to your specification. Cyclization, disulfide bridging, and other structural changes are handled through our peptide modification and custom peptide synthesis services, and this product sits in our cyclopeptides range. Material is supplied for research and manufacturing use only; customers are responsible for the regulatory and intellectual-property requirements that apply in their territory.
